| Code | Description | Claims | Beneficiaries | Total Paid |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
9,308 |
8,918 |
$1.09M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
5,438 |
5,199 |
$864K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
10,648 |
10,252 |
$856K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
3,405 |
3,289 |
$764K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
2,263 |
2,217 |
$86K |
| 80053 |
Comprehensive metabolic panel |
8,128 |
7,739 |
$81K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
721 |
717 |
$69K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
356 |
350 |
$68K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
690 |
684 |
$57K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
11,267 |
10,670 |
$56K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,850 |
1,782 |
$52K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
398 |
394 |
$30K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,310 |
1,285 |
$27K |
| 87631 |
|
250 |
242 |
$26K |
| T1015 |
Clinic visit/encounter, all-inclusive |
537 |
371 |
$26K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,432 |
2,346 |
$26K |
| 0100U |
|
57 |
55 |
$25K |
| 71046 |
Radiologic examination, chest; 2 views |
1,359 |
1,292 |
$22K |
| 84702 |
|
1,481 |
1,350 |
$21K |
| 76830 |
Ultrasound, transvaginal |
315 |
309 |
$21K |
| 80061 |
Lipid panel |
1,357 |
1,351 |
$18K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
2,017 |
1,927 |
$16K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
319 |
315 |
$16K |
| 70450 |
Computed tomography, head or brain; without contrast material |
205 |
197 |
$15K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
2,127 |
1,967 |
$15K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
304 |
295 |
$15K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
395 |
393 |
$14K |
| 84484 |
|
1,605 |
1,388 |
$13K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,104 |
1,066 |
$13K |
| 90670 |
|
190 |
189 |
$12K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
831 |
818 |
$10K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
208 |
198 |
$10K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
92 |
92 |
$9K |
| 36415 |
Collection of venous blood by venipuncture |
5,841 |
5,258 |
$8K |
| 76770 |
|
118 |
118 |
$8K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
456 |
441 |
$7K |
| 83690 |
|
1,702 |
1,624 |
$7K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
954 |
949 |
$6K |
| 76536 |
|
85 |
85 |
$6K |
| 83605 |
|
843 |
784 |
$5K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
150 |
98 |
$5K |
| 71045 |
Radiologic examination, chest; single view |
496 |
474 |
$5K |
| 90723 |
|
98 |
98 |
$5K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
256 |
252 |
$5K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
254 |
250 |
$5K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
675 |
654 |
$4K |
| 85027 |
|
782 |
741 |
$4K |
| 76642 |
|
95 |
84 |
$4K |
| 83880 |
|
174 |
165 |
$4K |
| 82805 |
|
160 |
142 |
$4K |
| 81001 |
|
1,531 |
1,481 |
$4K |
| 87481 |
|
54 |
53 |
$4K |
| Q3014 |
Telehealth originating site facility fee |
318 |
294 |
$3K |
| 90715 |
|
507 |
498 |
$3K |
| G0009 |
Administration of pneumococcal vaccine |
208 |
208 |
$3K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
14 |
14 |
$3K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
25 |
25 |
$3K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
305 |
292 |
$3K |
| 90680 |
|
81 |
81 |
$3K |
| 90686 |
|
215 |
215 |
$3K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
201 |
201 |
$3K |
| 73564 |
|
214 |
200 |
$3K |
| 72100 |
|
141 |
138 |
$3K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,950 |
1,878 |
$2K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
25 |
25 |
$2K |
| 73630 |
|
369 |
342 |
$2K |
| 73030 |
|
222 |
207 |
$2K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
65 |
63 |
$2K |
| 73610 |
|
231 |
222 |
$2K |
| 82607 |
|
188 |
187 |
$2K |
| 85610 |
|
692 |
530 |
$2K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
111 |
111 |
$2K |
| 82728 |
|
185 |
176 |
$2K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
17 |
17 |
$2K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
12 |
12 |
$2K |
| 90647 |
|
108 |
108 |
$2K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
50 |
25 |
$2K |
| G0008 |
Administration of influenza virus vaccine |
165 |
165 |
$2K |
| 83540 |
|
208 |
199 |
$2K |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
70 |
70 |
$2K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
12 |
12 |
$2K |
| 85379 |
|
206 |
204 |
$2K |
| 83735 |
|
316 |
280 |
$1K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
54 |
53 |
$1K |
| 77065 |
Tomosynthesis, mammo |
14 |
14 |
$1K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
57 |
54 |
$1K |
| 81003 |
|
592 |
573 |
$1K |
| 86803 |
|
99 |
99 |
$1K |
| 87430 |
|
217 |
215 |
$1K |
| 73110 |
|
176 |
169 |
$1K |
| 84439 |
|
137 |
133 |
$1K |
| 73130 |
|
204 |
184 |
$1K |
| 86140 |
|
467 |
449 |
$1K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
40 |
40 |
$1K |
| 87511 |
|
52 |
51 |
$946.73 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
106 |
71 |
$923.82 |
| 81025 |
|
349 |
342 |
$886.80 |
| 86900 |
|
216 |
198 |
$836.37 |
| 20610 |
|
62 |
56 |
$827.86 |
| 90633 |
|
13 |
13 |
$810.55 |
| 83655 |
|
77 |
77 |
$788.60 |
| 83550 |
|
169 |
164 |
$780.44 |
| 86850 |
|
197 |
194 |
$744.96 |
| 82375 |
|
162 |
144 |
$714.64 |
| 87186 |
|
117 |
111 |
$653.83 |
| 82570 |
|
97 |
95 |
$617.01 |
| 82248 |
|
108 |
105 |
$604.80 |
| 71250 |
|
13 |
13 |
$601.18 |
| 72125 |
Computed tomography, cervical spine; without contrast material |
14 |
12 |
$562.44 |
| 86901 |
|
216 |
198 |
$546.07 |
| 82962 |
|
425 |
318 |
$535.59 |
| 87150 |
|
12 |
12 |
$460.55 |
| 90473 |
|
45 |
45 |
$460.20 |
| 83050 |
|
160 |
142 |
$445.80 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
4,719 |
4,415 |
$419.34 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
13 |
12 |
$404.91 |
| 85652 |
|
133 |
130 |
$321.09 |
| 86618 |
|
14 |
14 |
$303.68 |
| 74018 |
|
30 |
30 |
$301.37 |
| 72040 |
|
15 |
14 |
$299.56 |
| 80076 |
|
49 |
48 |
$289.41 |
| 84100 |
|
68 |
54 |
$274.66 |
| 73080 |
|
44 |
42 |
$274.51 |
| 87340 |
|
39 |
39 |
$228.77 |
| 73502 |
|
12 |
12 |
$226.61 |
| 86780 |
|
13 |
13 |
$208.78 |
| A9585 |
Injection, gadobutrol, 0.1 ml |
276 |
258 |
$206.14 |
| 82565 |
|
44 |
42 |
$199.95 |
| J2704 |
Injection, propofol, 10 mg |
1,384 |
1,112 |
$181.24 |
| 85007 |
|
42 |
42 |
$154.42 |
| 90474 |
|
13 |
13 |
$131.50 |
| 83525 |
|
14 |
14 |
$131.23 |
| 87077 |
|
30 |
29 |
$125.28 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,505 |
2,338 |
$108.40 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
47 |
40 |
$108.08 |
| 82043 |
|
13 |
13 |
$101.76 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,124 |
1,024 |
$97.12 |
| 86762 |
|
12 |
12 |
$90.36 |
| 73090 |
|
13 |
13 |
$89.95 |
| J1790 |
Injection, droperidol, up to 5 mg |
98 |
76 |
$85.42 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,418 |
1,376 |
$84.69 |
| 94664 |
|
13 |
13 |
$67.95 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
260 |
224 |
$59.10 |
| 84460 |
|
13 |
12 |
$50.66 |
| 86592 |
|
12 |
12 |
$50.40 |
| 84450 |
|
13 |
12 |
$50.13 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
1,082 |
975 |
$50.03 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
13 |
13 |
$47.71 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
73 |
59 |
$45.86 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
933 |
909 |
$10.96 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
25 |
25 |
$10.37 |
| C9290 |
Injection, bupivacaine liposome, 1 mg |
13 |
13 |
$0.00 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
12 |
12 |
$0.00 |
| J7050 |
Infusion, normal saline solution, 250 cc |
209 |
156 |
$0.00 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
51 |
46 |
$0.00 |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
73 |
67 |
$0.00 |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
12 |
12 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
27 |
26 |
$0.00 |
| 90656 |
|
13 |
13 |
$0.00 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
148 |
134 |
$0.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
152 |
144 |
$0.00 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
41 |
36 |
$0.00 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
91 |
88 |
$0.00 |
| Q9957 |
Injection, perflutren lipid microspheres, per ml |
38 |
38 |
$0.00 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
58 |
55 |
$0.00 |